Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,778 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J. Song Y, et al. Among authors: kim ws. Lancet Oncol. 2024 Jan;25(1):117-125. doi: 10.1016/S1470-2045(23)00589-2. Epub 2023 Dec 9. Lancet Oncol. 2024. PMID: 38092009 Clinical Trial.
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS; Consortium for Improving Survival of Lymphoma (CISL) investigators. Kim SJ, et al. Among authors: kim hj, kim hk, kim js, kim ws. Eur J Cancer. 2012 Nov;48(17):3223-31. doi: 10.1016/j.ejca.2012.06.003. Epub 2012 Jul 4. Eur J Cancer. 2012. PMID: 22770877 Clinical Trial.
Plerixafor use for peripheral blood stem cell mobilization in Korea.
Kim SJ, Yoon DH, Yang DH, Eom HS, Cho SG, Yoon SS, Lee JH, Kim WS, Suh C. Kim SJ, et al. Among authors: kim ws. Blood Res. 2013 Jun;48(2):72-3. doi: 10.5045/br.2013.48.2.72. Blood Res. 2013. PMID: 23826573 Free PMC article. No abstract available.
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS. Kim SJ, et al. Among authors: kim js, kim ws. Eur J Cancer. 2013 Nov;49(16):3486-96. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1. Eur J Cancer. 2013. PMID: 23910494
Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group.
Kim SJ, Jung HA, Chuang SS, Hong H, Guo CC, Cao J, Hong XN, Suzuki R, Kang HJ, Won JH, Chng WJ, Kwong YL, Suh C, Song YQ, Zhu J, Tay K, Lim ST, Suzumiya J, Lin TY, Kim WS; Asia Lymphoma Study Group. Kim SJ, et al. Among authors: kim ws. J Hematol Oncol. 2013 Nov 16;6:86. doi: 10.1186/1756-8722-6-86. J Hematol Oncol. 2013. PMID: 24238138 Free PMC article.
Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
Kim SJ, Yang DH, Kim JS, Kwak JY, Eom HS, Hong DS, Won JH, Lee JH, Yoon DH, Cho J, Nam TK, Lee SW, Ahn YC, Suh C, Kim WS. Kim SJ, et al. Among authors: kim js, kim ws. Ann Hematol. 2014 Nov;93(11):1895-901. doi: 10.1007/s00277-014-2137-6. Epub 2014 Jun 20. Ann Hematol. 2014. PMID: 24947798 Clinical Trial.
Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma.
Yhim HY, Kim JS, Mun YC, Moon JH, Chae YS, Park Y, Jo JC, Kim SJ, Yoon DH, Cheong JW, Kwak JY, Lee JJ, Kim WS, Suh C, Yang DH; Consortium for Improving Survival of Lymphoma Study. Yhim HY, et al. Among authors: kim sj, kim js, kim ws. Biol Blood Marrow Transplant. 2015 Sep;21(9):1597-604. doi: 10.1016/j.bbmt.2015.05.003. Epub 2015 May 8. Biol Blood Marrow Transplant. 2015. PMID: 25963920 Free article. Clinical Trial.
Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.
Koh MS, Kim WS, Kim SJ, Oh SY, Yoon DH, Lee SI, Hong J, Song MK, Shin HJ, Kwon JH, Kim HJ, Do YR, Suh C, Kim HJ. Koh MS, et al. Among authors: kim hj, kim sj, kim ws. Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26. Int J Hematol. 2015. PMID: 26210384 Clinical Trial.
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.
Oh SY, Kim WS, Kim JS, Chae YS, Lee GW, Eom HS, Ryoo HM, Lee S, Kim SJ, Yoon DH, Won JH, Hong J, Park J, Lee SM, Hong JY, Park E, Kim HJ, Yang DH, Kim HJ, Suh C. Oh SY, et al. Among authors: kim hj, kim sj, kim js, kim ws. Leuk Lymphoma. 2016;57(6):1406-12. doi: 10.3109/10428194.2015.1099650. Epub 2015 Nov 16. Leuk Lymphoma. 2016. PMID: 26413982 Clinical Trial.
2,778 results